← Back to Patent Explorer
US5032575A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for enhancing healing of corneal endothelial wounds

Assignee: The Schepens Eye Research Institute Inc
•
Filing: 1989-04-13
•
Granted: 1991-07-16
•
Expires: 2009-04-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea prior to transplant. Examples of useful growth factors include, in addition to EGF and EGF-like compounds, fragments of EGF containing the receptor binding region, and EGF modified to improve stability, increase half-life, or enhance permeation into the eye. Examples of other non-steroidal antiinflammatories include aspirin, ibuprofen, and suprofen. The composition can be applied topically to the eye or delivered in a controlled fashion by means of a material such as a polymeric implant, gel, or liposomes. The effective dosage is that amount which promotes closure of corneal endothelial tissue and restores function, i.e., restores permeability, including both barrier function and pumping function.

Inventors

  • 👤 Arthur H. Neufeld
  • 👤 Nancy C. Joyce
  • 👤 Marcia M. Jumblatt

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 22:04
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1808; A61K31/00; A61K31/185; A61K31/19; A61K31/33; A61K31/38; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/60; A61K45/00; A61K45/06

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 93 words
A method for enhancing healing and restoring function of corneal endothelial tissue comprising manipulating migration, elongtion, and spreading of corneal endothelial cells by administering to corneal endothelial cells a composition wherein the active agent consists of an EGF-like growth factor which alters cell function by binding to a specific cell surface receptor, wherein said composition is administered in a pharmaceutically acceptable carrier for intraocular administration in an amount producing a concentration at the corneal endothelial cells of from approximately one and up to 50 ng EGF-like compound/ml solution contacting the corneal endothelial cells.
Claim 2
Independent Claim 93 words
A method for enhancing healing and restoring function of corneal endothelial tissue comprising manipulating migration, elongtion, and spreading of corneal endothelial cells by administering to corneal endothelial cells a composition wherein the active agent consists of an EGF-like growth factor which alters cell function by binding to a specific cell surface receptor, wherein said composition is administered in a pharmaceutically acceptable carrier for intraocular administration in an amount producing a concentration at the corneal endothelial cells of from approximately one and up to 50 ng EGF-like compound/ml solution contacting the corneal endothelial cells.
Claim 3
Dependent Claim 41 words
The method of claim 1 wherein 1 wherein the growth factor is selected from the group consisting of epidermal growth factor-like compounds, biologically active derivatives and homologous of epidermal growth factor, biologically active fragments of epidermal growth factor, and combinations thereof.
Claim 4
Dependent Claim 32 words
The method of claim 1 wherein an effective amount of the composition is that amount which promotes closure of corneal endothelial tissue and restoration of permeability function of the corneal endothelial tissue.
Claim 5
Dependent Claim 16 words
The method of claim 3 further comprising measuring corneal clarity to determine restoration of permeability function.
Claim 6
Dependent Claim 16 words
The method of claim 3 further comprising measuring corneal thickness to determine restoration of permeability function.
Claim 7
Dependent Claim 14 words
The method of claim 1 further comprising providing a nutritive solution for storing corneas.
Claim 8
Dependent Claim 16 words
The method of claim 1 wherein the composition is administered to the cornea prior to injury.
Claim 9
Dependent Claim 15 words
The method of claim 1 further comprising administering the composition in an intraocular irrigating solution.
Claim 10
Dependent Claim 22 words
The method of claim 8 wherein the composition is administered to the cornea at the time of or following injury or surgery.
Claim 11
Dependent Claim 15 words
The method of claim 1 further comprising providing growth factor in a controlled release material.
Claim 12
Dependent Claim 28 words
The method of claim 1 wherein the EDG-like compound is administered intraocularly to a concentration of approximately 10 ng EGF-like compound/ml of solution contacting the corneal endothelial cells.

References Cited (Backward Citations)

US4559343A Cited
JPS5965020A Cited
US4604234A Cited
EP0140998A1 Cited
EP0205051A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-07-15 1995-01-14 1995-07-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-07-15 1999-01-14 1999-07-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-07-15 2003-01-14 2003-07-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag